The possible use of SM-102 in other diseases besides cancer such as neurodegenerative disease and cardiovascular disease
Creators: name: Brian, Steven
Publisher: name: figshare
Year: 2023
Subjects: Molecular medicine

description: Introduction Heat shock protein 90 (Hsp90) is a highly conserved chaperone protein that is involved in the folding, stability, and function of many other proteins. Hsp90 has been shown to play a role in the pathogenesis of a variety of diseases, including cancer, neurodegenerative disease, and cardiovascular disease. SM-102 is a small molecule inhibitor of Hsp90 that has been found to have anti-cancer properties. SM-102 has been shown to induce the degradation of Hsp90-dependent proteins and to have anti-tumor effects in a variety of cancer cell lines. Additionally, SM-102 has been shown to have anti-inflammatory and neuroprotective effects in preclinical models of neurodegenerative disease. Recently, there has been growing interest in the potential use of SM-102 in other diseases besides cancer, including neurodegenerative disease and cardiovascular disease. This review will focus on the current understanding of the possible use of SM-102 in these diseases, including its mechanism of action, preclinical data, and the current state of its development as a therapeutic agent. Possible use in neurodegenerative diseases Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of neurons in the brain. These diseases are complex and poorly understood, but a growing body of evidence suggests that the molecular chaperone protein heat shock protein 90 (Hsp90) may play a role in their development and progression. Hsp90 is involved in the folding, stability, and function of many disease-associated proteins, such as huntingtin, tau, and alpha-synuclein, which are implicated in the development and progression of neurodegenerative diseases. Inhibition of Hsp90 by SM-102 may lead to the degradation of these proteins and a reduction in their toxic effects on neurons. This is an attractive target for the development of new therapeutic strategies for neurodegenerative diseases. Additionally, Hsp90 is involved in the regulation of the immune system, which plays a role in many neurodegenerative diseases. Inflammation has been implicated in the development and progression of neurodegenerative diseases, and the inhibition of Hsp90 by SM-102 may have immune-modulatory effects that are beneficial for these diseases. Studies in animal models of neurodegenerative diseases have shown that the inhibition of Hsp90 by SM-102 can reduce the accumulation of disease-associated proteins and ameliorate the symptoms of these diseases. For example, in a mouse model of Huntington's disease, treatment with SM-102 was found to reduce the accumulation of huntingtin and improve motor function. These results suggest that the inhibition of Hsp90 by SM-102 may have therapeutic potential in neurodegenerative diseases. Possible use in cardiovascular disease Cardiovascular disease (CVD) is a major cause of death and disability worldwide, and a growing body of evidence suggests that heat shock protein 90 (Hsp90) may play a role in the development and progression of CVD. Hsp90 is involved in the folding, stability, and function of many disease-associated proteins, such as those involved in the regulation of blood pressure and the contractile function of heart muscle. Inhibition of Hsp90 by SM-102 may lead to the degradation of these proteins and a reduction in their toxic effects on the heart and blood vessels. Studies in animal models of CVD have shown that the inhibition of Hsp90 by SM-102 can improve cardiovascular function and reduce the risk of heart disease. For example, in a mouse model of hypertension, treatment with SM-102 was found to reduce blood pressure and improve cardiovascular function. These results suggest that the inhibition of Hsp90 by SM-102 may have therapeutic potential in CVD. Additionally, Hsp90 is involved in the regulation of the immune system, which plays a role in CVD. Inflammation has been implicated in the development and progression of CVD, and the inhibition of Hsp90 by SM-102 may have immune-modulatory effects that are beneficial for these diseases. Conclusion SM-102 is a small molecule inhibitor of heat shock protein 90 (Hsp90) that has been found to have anti-cancer properties. The inhibition of Hsp90 by SM-102 has been shown to have therapeutic potential in a variety of diseases, including cancer, neurodegenerative disease, and cardiovascular disease. In the field of cancer, SM-102 has been shown to induce the degradation of Hsp90-dependent proteins and to have anti-tumor effects in a variety of cancer cell lines. In the field of neurodegenerative disease, SM-102 has been shown to have anti-inflammatory and neuroprotective effects in preclinical models. In the field of cardiovascular disease, the inhibition of Hsp90 by SM-102 has been shown to improve cardiovascular function and reduce the risk of heart disease in animal models. Despite these promising results, much more research is needed to fully understand the potential therapeutic applications of SM-102 in these diseases. Clinical trials will be necessary to evaluate the safety and efficacy of SM-102 as a therapeutic agent. In conclusion, SM-102 is a promising therapeutic candidate with the potential to treat a variety of diseases, including cancer, neurodegenerative disease, and cardiovascular disease. The ongoing research in these areas has the potential to lead to new treatment options for patients suffering from these debilitating conditions.